Low-Dose Pioglitazone in Patients With NASH (AIM 2)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 166 participants.
Also called NCT04501406
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 166 participants
- Registry
-
NCT04501406
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT04501406. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-15 (actual); primary completion 2027-08-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Low-Dose Pioglitazone in Patients With NASH (AIM 2)
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Condition
- Nonalcoholic Steatohepatitis
- Intervention (Drug)
- Pioglitazone
- Intervention (Other)
- Placebo
- Lead sponsor
- University of Florida
- Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Record details
- Record id
cardio:ct-nct04501406- Content hash
9f0d32d2d79ee0f7a8ed52f7091b7a01bc222c214a2b047624f9ce1c4fd6a92c